Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.54 |
| ▸ | ITGAV | P06756 | 1/20 | 0.54 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22923277 | 0.89 | KLK5 (0.54) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL10890972 | 0.87 | ITGB3 (0.61) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL16448191 | 0.87 | ACE (0.64) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL9502547 | 0.87 | ACE (0.64) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL24725329 | 0.86 | ACE (0.65) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL3501896 | 0.86 | ACE (0.65) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL6247655 | 0.86 | ACE (0.56) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL3501894 | 0.86 | ACE (0.65) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL2729384 | 0.86 | ITGB3 (0.58) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL6247651 | 0.86 | ACE (0.56) | ACEITGB3ITGA2BITGB1ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586988-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-8557781-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8399614-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8153758-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20080317670-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | AMBRX, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080194459-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080187491-A1 | For diagnosis, genetic engineering; post-translation modification | AMBRX, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080118464-A1 | For diagnosis, genetic engineering; post-translation modification | AMBRX, INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317670-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | PTMS, DNPEP, ANPEP | ACE 1073/4885ITGB3 1780/4885ITGA2B 2020/4885 |
| US-20080118464-A1 | For diagnosis, genetic engineering; post-translation modification | PTMS, ANPEP, AADAT | ACE 984/4885ITGB3 2447/4885ITGA2B 2645/4885 |
| US-20080187491-A1 | For diagnosis, genetic engineering; post-translation modification | PTMS, ANPEP, AADAT | ACE 984/4885ITGB3 2447/4885ITGA2B 2645/4885 |
| US-20080194459-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, ANPEP, PTMS | ACE 641/4885ITGB3 2010/4885ITGA2B 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.